Undervalued Small Caps With Insider Buying

Results

63

14 new

Smaller, under-the-radar companies, backed by insider buying, presenting a compelling opportunity for investors seeking undervalued gems.

63 companies

	Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield	Industry
	BMRC	US$28.94	9.0%	14.0%	US$442.9m	US$28.80	1.2	108.7%	3.5%	Banks
	FNLC	US$35.53	4.2%	34.6%	US$392.6m	n/a	1.4	n/a	4.2%	Banks
	MDV New	US$17.40	-2.6%	20.3%	US$207.4m	US$18.67	1.1	149.5%	6.9%	Real Estate
	KINS	US$19.69	12.5%	29.7%	US$275.6m	US$21.50	9.2	20.8%	1.0%	Insurance
	ILPT	US$9.00	3.4%	95.2%	US$591.3m	US$9.65	1.3	14.1%	2.2%	Real Estate
	PEBO	US$39.16	3.8%	23.0%	US$1.4b	US$38.17	1.2	14.2%	4.3%	Banks
	SMWB	US$6.59	27.7%	-22.5%	US$537.0m	US$5.00	2.0	112.6%	n/a	Software
	ONT New	US$20.62	15.8%	-7.9%	US$730.4m	US$27.33	168.4	98.7%	n/a	Commercial Services
	APPN	US$23.76	14.1%	-21.2%	US$1.7b	US$26.20	1970.9	108.9%	n/a	Software
	ANGX	US$3.54	12.0%	-69.5%	US$684.1m	US$8.00	1.7	59.0%	n/a	Media
	UNB	US$24.68	-5.8%	-12.9%	US$113.9m	n/a	1.4	n/a	5.8%	Banks
	BOTJ	US$25.92	5.6%	81.8%	US$115.9m	n/a	1.4	n/a	1.5%	Banks
	PAX	US$11.00	2.2%	-23.1%	US$1.8b	US$15.57	24.6	35.7%	5.9%	Diversified Financials
	GABC	US$48.06	3.3%	19.5%	US$1.8b	US$49.40	1.5	5.8%	2.6%	Banks
	ANIK	US$15.18	3.1%	34.9%	US$194.7m	US$17.50	1.7	67.6%	n/a	Pharmaceuticals & Biotech
	BY	US$38.33	5.0%	37.0%	US$1.7b	US$37.40	1.4	4.4%	1.3%	Banks
	TGEN New	US$4.93	-8.4%	-46.0%	US$156.2m	US$8.83	5.6	119.5%	n/a	Capital Goods
	CBAN New	US$20.49	-3.7%	19.5%	US$425.1m	US$24.13	1.1	36.2%	2.3%	Banks
	UMH	US$15.28	-0.3%	-10.9%	US$1.3b	US$19.43	2.3	26.6%	5.9%	Real Estate
	KRO	US$6.13	-6.6%	-6.8%	US$728.3m	US$6.50	0.4	5.6%	3.3%	Materials
	FRST New	US$16.37	4.4%	48.3%	US$405.5m	US$17.88	0.9	2.7%	2.4%	Banks
	MRBK	US$20.27	2.1%	47.4%	US$238.2m	US$23.00	1.2	21.5%	2.8%	Banks
	PBHC	US$16.23	1.2%	8.1%	US$99.4m	n/a	0.8	n/a	2.5%	Banks
	CMTV New	US$39.13	-2.6%	93.2%	US$218.6m	n/a	1.9	n/a	2.6%	Banks

Page 1 of 2